Chongqing Lummy Pharmaceutical Co., Ltd.
-
Founded in:
1999-09-06 -
Country:
China -
Address:
No. 99, Yuma Road, Nan'an District, Chongqing -
Tax NO.:
915000006219193432 -
Registered Funds:
1,055,911,205 yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Dexamethasone sodium phosphate |
Adrenal cortex hormone drugs. They have anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Their mechanism of action is as follows: (1) Anti-inflammatory effect: reduce and prevent tissue response to inflammation, inhibit inflammatory cell aggregation, phagocytosis, lysosomal enzyme release and the synthesis and release of inflammatory chemical mediators. (2) Immunosuppressive effect: prevent or inhibit cell-mediated immune response, reduce the number of T lymphocytes, monocytes and eosinophils, reduce the ability of immunoglobulins to bind to cell surface receptors, inhibit interleukin synthesis and release, reduce the transformation of T lymphocytes to lymphoblasts and reduce the expansion of primary immune response; also reduce the passage of immune complexes through the basement membrane, reduce complement components and immunoglobulin concentrations.
More
Adrenal cortex hormone drugs. They have anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Their mechanism of action is as follows: (1) Anti-inflammatory effect: reduce and prevent tissue response to inflammation, inhibit inflammatory cell aggregation, phagocytosis, lysosomal enzyme release and the synthesis and release of inflammatory chemical mediators. (2) Immunosuppressive effect: prevent or inhibit cell-mediated immune response, reduce the number of T lymphocytes, monocytes and eosinophils, reduce the ability of immunoglobulins to bind to cell surface receptors, inhibit interleukin synthesis and release, reduce the transformation of T lymphocytes to lymphoblasts and reduce the expansion of primary immune response; also reduce the passage of immune complexes through the basement membrane, reduce complement components and immunoglobulin concentrations. |
55203-24-2 | 25 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Dexamethasone sodium phosphate |
Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. 1. Anti-inflammatory effect: This product reduces and prevents tissue response to inflammation, thereby reducing the manifestations of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. This product also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins.
More
Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. 1. Anti-inflammatory effect: This product reduces and prevents tissue response to inflammation, thereby reducing the manifestations of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. This product also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins. |
55203-24-2 | 25 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Dexamethasone sodium phosphate |
Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. 1. Anti-inflammatory effect: This product reduces and prevents tissue response to inflammation, thereby reducing the manifestations of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. This product also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins.
More
Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. 1. Anti-inflammatory effect: This product reduces and prevents tissue response to inflammation, thereby reducing the manifestations of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. This product also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins. |
55203-24-2 | 25 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Levofloxacin hydrochloride |
This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, some Escherichia coli, influenza bacillus, Pseudomonas aeruginosa, gonococci, etc. It also has good antibacterial effects on some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.
More
This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, some Escherichia coli, influenza bacillus, Pseudomonas aeruginosa, gonococci, etc. It also has good antibacterial effects on some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc. |
177325-13-2 | 18 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Levofloxacin hydrochloride |
Levofloxacin is the L-isomer of ofloxacin (racemate) and is a quinolone antibacterial drug. Its antibacterial mechanism is to inhibit topoisomerase IV and DNA gyrase (topoisomerase II) required for bacterial DNA replication, transcription, repair and recombination. It has antibacterial effects on a variety of Gram-negative and Gram-positive bacteria, and has bactericidal activity when the concentration is equal to or slightly higher than the inhibitory concentration.
More
Levofloxacin is the L-isomer of ofloxacin (racemate) and is a quinolone antibacterial drug. Its antibacterial mechanism is to inhibit topoisomerase IV and DNA gyrase (topoisomerase II) required for bacterial DNA replication, transcription, repair and recombination. It has antibacterial effects on a variety of Gram-negative and Gram-positive bacteria, and has bactericidal activity when the concentration is equal to or slightly higher than the inhibitory concentration. |
177325-13-2 | 18 |